Category: cell therapies

  • Billionaire-backed “rejuvenation” start-up Altos Labs launches operations

    Just months after the venture was unveiled, controversial biotechnology company Altos Labs has officially launched with $3 billion in funding secured from investors. Dubbed an ‘anti-ageing’ company, Altos has gained mainstream attention for its focus on ‘rejuvenation’ and biological reprogramming technology. While the specific research goals have been kept a closely guarded secret, some scientists […]

  • Cell Line Development and Characterization: An Ocean of Opportunities for Service Providers

    The growing pipeline of monoclonal antibodies, vaccines, enzymes, biosimilars and other therapeutic proteins have created an ever- increasing demand for highly- productive and stable cell lines. Many of the recombinant biotherapeutic products, produced in cellular systems, have been translated into commercial successes; these include ALPROLIX®, ELOCTATE® and ELAPRASE®.  Given their impact on the overall quality […]

  • Multi-Functional Cell Therapies Summit

    Advance Cutting-Edge Research and Development with Next-Generation Cell Therapies, to Deliver Best-in-Class Products to Patients in Need Cell therapies hold life-saving potential for patients, and the race is on to develop a best-in-class, living, ‘thinking’ drugs. Relapse rates and barriers to solid tumor efficacy mean the cell therapy industry must innovate, now more than ever. […]